Series A · 2026-11-12 · Healthcare
Biomatter raises $18.0M
62
AI Score
Amount
$18.0M
Round
Series A
Lead
Astanor
HQ
Vilnius, LT
Why it matters: The round shows how proprietary lab data, not just model architecture, is becoming the moat in AI enzyme design, with named pharma and industrial customers already using the output.
Biomatter, a Lithuanian biotech using AI to design custom enzymes, raised $18M in an oversubscribed Series A led by Astanor.
- Participants:
- UVC Partners, Inventure, Metaplanet
- Source:
- Tech Funding News ↗ · Midu summary
Deal Dossier PRO
Pro feature
Deal Dossier for Biomatter
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing